Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Resources

AJMC Report Confirms Most Drugs Dispensed in ‘Protected Classes’ Are Generics

11/19/2020

 
Picture
​A recent paper in the American Journal of Managed Care confirms that patients who are prescribed medications in Medicare’s “six protected classes” are consistently utilizing lower-cost generics, despite arguments from insurance companies who have said they have limited tools to contain costs for these treatments. Indeed, the authors concluded that generic dispensing rates (GDR) in the protected classes are often much higher than their non-protected counterparts — and are at least consistent with the dispensing rates among other classes of drugs. In fact, the paper suggests that plans that dispense generics at a lower rate do so to capture larger rebates from drug manufacturers, rather than to maximize access for their beneficiaries and minimize what they would pay out-of-pocket.


Read More

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    March 2021
    February 2021
    November 2020
    January 2020
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    July 2018
    June 2018
    March 2018
    January 2018
    September 2017
    August 2016
    June 2016
    March 2016
    September 2014
    March 2014
    February 2014
    January 2014
    July 2011
    September 2010
    March 2010
    July 2008
    January 2008
    December 2003

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
E-Mail 
© COPYRIGHT 2018. ALL RIGHTS RESERVED.